About Us |
Contact Us |
LexisNexis Business Solutions
Faced with increasing globalization and supply chain complexity, pharmaceutical companies have the daunting task of managing risks—ranging from counterfeiting to piracy—that could potentially threaten patient safety. What’s more, the pharmaceutical industry is not immune to the impact of stricter laws and sanctions to counter bribery and corruption.
On a recent webinar, LexisNexis Segment Leader for Entity Due Diligence and Monitoring Mark Dunn discussed how anti-money laundering, anti-bribery and corruption enforcement trends effecting the pharmaceutical industry. He also reviewed regulator expectations for staying compliant within a global business environment and shared best practices around risk assessment and why a healthy due- diligence strategy is the best approach to reducing regularity risk.